Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 2Unknown 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60Leukemia 32Gastrointestinal Stromal Tumors 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Chronic-Phase 21Blast Crisis 9Philadelphia Chromosome 8Neoplasm Metastasis 8Melanoma 8Lung Neoplasms 8Brain Neoplasms 7Sarcoma 6Prostatic Neoplasms 6Neoplasms 6Recurrence 5Ovarian Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Small Cell Lung Carcinoma 4Primary Myelofibrosis 4Polycythemia Vera 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Acute 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Myeloid 4Dermatofibrosarcoma 4Carcinoma, Ovarian Epithelial 4Breast Neoplasms 4Osteosarcoma 3Neuroectodermal Tumors, Primitive, Peripheral 3

Interventions

Hydroxyurea 7Bevacizumab 7Everolimus 6lutetium Lu 177 dotatate 4Magnetic Resonance Spectroscopy 4pembrolizumab 3abemaciclib 3Sunitinib 3Imatinib Mesylate 3vistusertib 2gallium Ga 68 dotatate 2arginyllysine 2aldesleukin 2Whole Body Imaging 2Specimen Handling 2Radiotherapy 2Octreotide 2Nivolumab 2Cyclophosphamide 2Amino Acids 290Y-octreotide, DOTA-Tyr(3)- 2vatalanib 1tozuleristide 1sargramostim 1regorafenib 1pasireotide 1neratinib 1fludarabine phosphate 1fludarabine 1dexamethasone acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Meningioma × Imatinib Mesylate × Clear all
NCT00045734 2017-05-15

Imatinib Mesylate in Treating Patients With Recurrent Meningioma

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 9 charts
CNS

Brain Neoplasms, Meningioma

NCT00904735 2013-08-12

Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma

National Cancer Institute (NCI)

Phase 2 Unknown
76 enrolled
CNS

Brain Neoplasms, Meningioma, Central Nervous System Neoplasms

NCT00354913 2013-01-18

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Duke University

Phase 2 Completed
21 enrolled 8 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Meningioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡